GSK plc (GSK)
NYSE: GSK · Real-Time Price · USD
47.18
-0.14 (-0.30%)
At close: Nov 14, 2025, 4:00 PM EST
47.19
+0.01 (0.02%)
After-hours: Nov 14, 2025, 7:57 PM EST
GSK Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for GSK in the last 12 months.
Price Target: n/a
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for GSK is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 5 | 5 | 5 | 5 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Initiates n/a | Hold → Strong Buy | Initiates | n/a | n/a | Oct 27, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 12, 2024 |
| Guggenheim | Guggenheim | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Oct 31, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 8, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $53 → $53 | Strong Buy | Maintains | $53 → $53 | +12.34% | Jul 2, 2024 |
Financial Forecast
Revenue This Year
33.29B
from 31.38B
Increased by 6.08%
Revenue Next Year
35.02B
from 33.29B
Increased by 5.22%
EPS This Year
1.69
from 0.62
Increased by 171.24%
EPS Next Year
1.86
from 1.69
Increased by 10.53%
Financial currency is GBP. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 34.5B | 37.4B | |||
| Avg | 33.3B | 35.0B | |||
| Low | 31.2B | 32.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.9% | 12.4% | |||
| Avg | 6.1% | 5.2% | |||
| Low | -0.7% | -1.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.85 | 2.10 | |||
| Avg | 1.69 | 1.86 | |||
| Low | 1.35 | 1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 197.4% | 24.5% | |||
| Avg | 171.2% | 10.5% | |||
| Low | 117.2% | -10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.